Post-ERCP pancreatitis: New momentum

Endoscopy

Volumn 34, Issue 4, 2002, Pages 325-329

  Tabenstein, Thomas ^a   Hahn, E G ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMYLASE; ANALGESIC AGENT; CHEMOKINE; CONTRAST MEDIUM; CYTOKINE; GABEXATE MESILATE; GLYCERYL TRINITRATE; HEPARIN; INTERLEUKIN 10; LOW MOLECULAR WEIGHT HEPARIN; NITRATE; OCTREOTIDE; PREDNISONE; SEDATIVE AGENT; SOMATOSTATIN;

AGE; ANAMNESIS; ANTIINFLAMMATORY ACTIVITY; BILE DUCT; CANNULATION; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; ECONOMIC ASPECT; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPIC SPHINCTEROTOMY; ENDOSCOPIC THERAPY; ENDOTHELIUM CELL; FOLLOW UP; GENDER; HIGH RISK PATIENT; HUMAN; HYPERAMYLASEMIA; INCIDENCE; INJECTION; LABORATORY TEST; LEUKOCYTE; MANOMETRY; META ANALYSIS; NURSE; PAIN; PANCREAS; PANCREAS DUCT; PANCREAS INJURY; PANCREAS JUICE; PANCREATITIS; PAPILLEDEMA; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; RELAPSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SPHINCTEROTOMY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STENT; SYMPTOM; VATER PAPILLA STENOSIS;

ACUTE DISEASE; BILIARY TRACT DISEASES; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; PANCREATITIS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; RISK FACTORS;

EID: 0036208971     PISSN: 0013726X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-23651     Document Type: Review

References (35)

1. Post-endoscopic retrograde cholangiopancreatography pancreatitis and hyperamylasaemia: Patient-related and operative risk factors
2. Sphincter of Oddi dysfunction: Pancreatobiliary sphincterotomy with pancreatic stent placement has a lower rate of pancreatitis than biliary sphincterotomy alone
3. A prospective, randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis
4. Complications of endoscopic biliary sphincterotomy
5. Risk factors for post-ERCP pancreatitis: A prospective, multicenter study
6. Major early complications from diagnostic and therapeutic ERCP: A prospective multicenter study
7. Analysis of risk factors of endoscopic sphincterotomy techniques: Preliminary results of a prospective study with emphasis on the reduced risk of acute pancreatitis under low-dose anticoagulation
8. Complications of endoscopic sphincterotomy: Can heparin prevent acute pancreatitis following endoscopic retrograde cholangio-pancreatography?
9. Complications of diagnostic and therapeutic ERCP: A prospective multicenter study
10. ERCP and endoscopic sphincterotomy induced pancreatitis
11. The impact of skill and experience of the endoscopist on the outcome of endoscopic sphincterotomy
12. Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction
13. Stent placement in the pancreatic duct prevents pancreatitis after endoscopic sphincter dilation for removal of bile duct stones
14. Mechanism of pancreatitis caused by ERCP
15. Complications of endoscopic sphincterotomy: A prospective series with emphasis on the increased risk associated with sphincter of Oddi dysfunction and nondilated ducts
16. Morphology of the pancreatic duct epithelium after traumatization of the papilla of Vater or endoscopic retrograde pancreatography with contrast media in cats
17. Endoscopic therapy of complete and partial pancreatic duct disruptions
18. The role of endoscopic retrograde pancreatography in the treatment of traumatic pancreatic duct injury
19. A pancreatic ductal leak should be sought to direct treatment in patients with acute pancreatitis
20. Prevention of post-ERCP pancreatitis
21. Endoscopic sphincterotomy complications and their management: An attempt at consensus
22. Incidence of post-endoscopic retrograde-cholangiopancreatography/sphincterotomy pancreatitis depends upon definition criteria
23. Immunologic mechanisms in acute pancreatitis
24. Octreotide 24-h prophylaxis in patients at high risk for post-ERCP pancreatitis: Results of a multicenter, randomized, controlled trial
25. Prospective randomized double-blind placebo-controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreatography-induced pancreatitis
26. Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography
27. Medical treatment can prevent pancreatic injury after ERCP: A meta-analysis
28. Double blind randomised controlled trial of effect of metoprolol on myocardial ischaemia during endoscopic cholangiopancreatography
29. IL-10 in post-ERCP pancreatitis
30. A randomized, double blind study of interleukin 10 for the prevention of ERCP-induced pancreatitis
31. Early recognition of post-ERCP pancreatitis by clinical assessment and serum pancreatic enzymes
32. Serum amylase measured four hours after endoscopic sphincterotomy is a reliable predictor of postprocedure pancreatitis
33. Twenty-four-hour serum amylase predicting pancreatic reaction after endoscopic sphincterotomy
34. Recognition of ERC-induced pancreatitis in patients with choledocholithiasis by an analysis of laboratory findings
35. Prediction of pancreatitis following endoscopic retrograde cholangiopancreatography by the 4-h post procedure amylase level